Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Lineagen received early financing of $5.8M on 2008-12-31.
| Series | Round size | Date |
|---|---|---|
| Series A | $5.8M | 12/2008 |
| Debt Financing | $1.1M | 06/2010 |
| Series A | $10.8M | 08/2010 |
| Series B | $16M | 11/2011 |
| Debt Financing | $11.6M | 04/2013 |
| Series C | $3.5M | 12/2013 |
| Series C | $12.2M | 01/2015 |
| Investors | Security type |
|---|---|
| Sanderling Ventures | Series A |
| vSpring Capital | Series A |
| Mesa Verde Venture Partners | Series A |
| PrairieGold Venture Partners | Series A |
| Sanderling Ventures | Series A |
| vSpring Capital | Series A |
| Mesa Verde Venture Partners | Series A |
| PrairieGold Venture Partners | Series B |
| Sanderling Ventures | Series B |
| vSpring Capital | Series B |
| Mesa Verde Venture Partners | Series B |
| Archipel Capital | Series C |
| PrairieGold Venture Partners | Series C |
| Sanderling Ventures | Series C |
| Mesa Verde Venture Partners | Series C |
| Kickstart | Series C |
| University Venture Fund | Series C |
| Hatteras Funds | Series C |
| Signal Peak Ventures | Series C |
| PrairieGold Venture Partners | Series C |
| Archipel Capital | Series C |
| Sanderling Ventures | Series C |
| Mesa Verde Venture Partners | Series C |
| HealthQuest Capital | Series C |
| Petra Capital Partners | Series C |
| University Venture Fund | Series C |
| Mountain Group Capital | Series C |
| Signal Peak Ventures | Series C |
| Kickstart Ventures | Series C |
Lineagen's top competitor, Sarepta Therapeutics, earned an annual revenue of $1.9B.
Lineagen's smallest competitor is Epic Sciences with revenue of $1.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Foundation Medicine | $94,749 | $152.9M | 1,300 | 24 |
| NeoGenomics Laboratories | $62,740 | $660.6M | 1,500 | 55 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 15 |
| Genocea | $53,221 | - | 59 | - |
| Quidel | $71,489 | $1.7B | 1,500 | - |
| Geron | $56,851 | $77.0M | 15 | - |
| Aastrom Biosciences | $51,812 | - | - | - |
| Epic Sciences | $45,673 | $1.0M | 10 | 4 |
| Marcus Autism Center | $43,287 | $3.4M | 99 | - |
| Intercept Pharmaceuticals | $93,850 | $285.7M | 437 | - |
Zippia gives an in-depth look into the details of Lineagen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Lineagen. The employee data is based on information from people who have self-reported their past or current employments at Lineagen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Lineagen. The data presented on this page does not represent the view of Lineagen and its employees or that of Zippia.
Lineagen may also be known as or be related to LINEAGEN, LineaGen, Inc, LineaGen, Inc., Lineagen, Lineagen Inc and Lineagen, Inc.